2904131|t|Neurobehavioral effects of intrathecal somatostatinergic treatment in subhuman primates.
2904131|a|We infused somatostatin and its long-acting analogue (SMS 201-995) into the intracranial subarachnoid space of eight monkeys. Chronic infusions of SMS 201-995 produced marked neurotoxic effects characterized by truncal ataxia, dysmetria, and severe bradykinesia, with normal level of consciousness. Subcutaneous injection of apomorphine, a dopaminergic agonist, promptly reversed these effects. Further studies are required before intrathecal somatostatin replacement therapy can be offered to patients with Alzheimer's disease.
2904131	100	112	somatostatin	Gene	6750
2904131	143	154	SMS 201-995	Chemical	MESH:D015282
2904131	236	247	SMS 201-995	Chemical	MESH:D015282
2904131	264	274	neurotoxic	Disease	MESH:D020258
2904131	300	314	truncal ataxia	Disease	MESH:D001259
2904131	316	325	dysmetria	Disease	MESH:D002524
2904131	338	350	bradykinesia	Disease	MESH:D018476
2904131	414	425	apomorphine	Chemical	MESH:D001058
2904131	429	441	dopaminergic	Chemical	MESH:D004298
2904131	532	544	somatostatin	Gene	6750
2904131	583	591	patients	Species	9606
2904131	597	616	Alzheimer's disease	Disease	MESH:D000544
2904131	Positive_Correlation	MESH:D015282	MESH:D020258
2904131	Positive_Correlation	MESH:D015282	MESH:D018476
2904131	Negative_Correlation	MESH:D001058	MESH:D001259
2904131	Negative_Correlation	MESH:D001058	MESH:D018476
2904131	Positive_Correlation	MESH:D015282	MESH:D001259
2904131	Positive_Correlation	MESH:D015282	MESH:D002524
2904131	Association	MESH:D000544	6750
2904131	Positive_Correlation	MESH:D001058	MESH:D004298
2904131	Negative_Correlation	MESH:D001058	MESH:D002524

